Pretests for a Study on Quantitative Information in Direct-to-Consumer Television Advertisements

Data to Support Drug Product Communications as Used by the Food and Drug Administration

Appendix C -- Pretest 1 Questionnaire

Pretests for a Study on Quantitative Information in Direct-to-Consumer Television Advertisements

OMB: 0910-0695

Document [doc]
Download: doc | pdf


Quantitative TV Study Pretest 1

Survey Questionnaire



PRETEST 1 OBJECTIVES

  1. Select numbers for the simple and complex benefit information in Study 1.

  2. Ensure the simple and complex manipulations are operationalized correctly and perceived as different in terms of complexity.




INTRODUCTION

Thank you for agreeing to participate in this study today.


First, we’d like to ask you some questions about treatments for cataracts, an eye condition associated with older age that causes cloudy vision.


YOUR HEALTH


Q1. In general, how much do know about cataracts? (perceived medical condition knowledge)

Nothing at all

Only a little bit

Some

A lot


Q2. Do you have or have you had cataracts? (medical condition history)

Yes – Currently have cataracts

Yes – Previously had cataracts

Never had cataracts

Don't know


Q3. [IF YES] Have you ever had cataract surgery? (treatment history)

Yes

No

Don't know


Q4. [IF NEVER HAD / DON’T KNOW] How likely do you think it is that you will get cataracts? (medical condition perceived risk)


1 2 3 4 5 6

Not at all Extremely

Likely Likely



Q5. Have any of your close family members—such as parents, brothers, or sisters—ever had cataracts? (family medical condition history)

Yes

No

Don’t know


Q6. Have you had any vision problems—other than needing contacts or glasses—in the past 10 years? (history of vision problems)

Yes

No

Don’t know



TREATMENTS FOR CATARACTS


Surgery is one treatment for cataracts. We’d like to ask what you think about the effectiveness of cataract surgery. If you aren’t certain, please provide your best guess.


Q7. After having cataract surgery, how much better can most people see? (perceived efficacy, magnitude – surgery)


0% to 100% better (sliding scale)


Q8. If 100 people have cataract surgery, how many will have ANY improvement in their vision? (perceived efficacy, likelihood – surgery)


0 (sliding scale) 100

No one Everyone


[DISPLAY FOLLOWING QUESTIONS ON SAME SCREEN]

[RANDOMIZE ORDER: (1) REALLY WELL DID NOT WORK WELL OR (2) DID NOT WORK WELL REALLY WELL]


The following questions ask about [Drug X], a prescription drug for improving vision in people who have cataracts. (percentages associated with efficacy levels)


Q9. If [Drug X] worked REALLY WELL, it would improve a person’s vision by __%.

Q10. If [Drug X] worked REALLY WELL, it would improve vision in __% of people who take it.


Q11. If [Drug X] worked WELL, it would improve a person’s vision by __%.

Q12. If [Drug X] worked WELL, it would improve vision in __% of people who take it.


Q13. If [Drug X] worked SOMEWHAT WELL, it would improve a person’s vision by __%.

Q14. If [Drug X] worked SOMEWHAT WELL, it would improve vision in __% of people who take it.


Q15. If [Drug X] DID NOT WORK WELL, it would improve a person’s vision by __%.

Q16. If [Drug X] DID NOT WORK WELL, it would improve vision in __% of people who take it.


[Show the following three questions in random order] (efficacy levels associated with percentages)


Q17. Imagine that [Drug X] improved vision by 20%. How effective would you say [Drug X] is?


1

2

3

4

5

6

Not at all effective





Extremely

effective


Q18. Imagine that [Drug X] improved vision by 40%. How effective would you say [Drug X] is?


1

2

3

4

5

6

Not at all effective





Extremely

effective


Q19. Imagine that [Drug X] improved vision by 60%. How effective would you say [Drug X] is?


1

2

3

4

5

6

Not at all effective





Extremely

effective


Please read the following statement.


[Randomly assign participants to view four of the following statements, presented in random order. The statement should appear on screen with the FOLLOWING questions].


Version A [CONTROL]


[Drug X] has been shown to improve vision.


Version B


[Drug X] has been shown to improve vision by 40%.


Version C


In 60% of people who have cataracts, Drug X has been shown to improve vision by 40%.


Version D


In 60% of people who have cataracts, Drug X has been shown to improve vision by an average of 40%.


Version E


In a clinical trial of 301 people who had cataracts, 60% of those who took Drug X had a 40% improvement in their vision.


Version F


Drug X was tested in two clinical trials of people who had cataracts. In one trial, 62% of people who took Drug X had a 38% improvement in their vision. In the other trial, 58% of people who took Drug X had a 42% improvement in their vision.



Q20. In your own words, please explain what this statement means. (open-ended) (efficacy claim comprehension)


Q21. Please complete the following sentence: [Drug X] improves vision by __%. (efficacy claim accuracy – magnitude)

___% [permit numbers from 0-100; also permit ranges (e.g., 40-60%)]


Q22. If 100 people take [Drug X], how many will have better vision? (efficacy claim accuracy – likelihood)

___% [permit numbers from 0-100; also permit ranges (e.g., 40-60%)]


Q23. Please rate the statement on the following attributes: (efficacy claim clarity)


1 2 3 4 5 6

Not at all Extremely

Understandable Understandable

1 2 3 4 5 6

Not at all Extremely

Clear Clear


1 2 3 4 5 6

Not at all Extremely

Easy to Read Easy to Read

1 2 3 4 5 6

Not at all Extremely

Complex Complex



DEBRIEF


The purpose of this research is to understand how people interpret prescription drug information in advertisements. In order to get a real-life reaction to this information, we used a pretend product in this study. [Drug X] is not a real product and is not available for sale. Please see your healthcare professional for questions about cataracts.


You have been very helpful. Thank you very much for your participation!


4

File Typeapplication/msword
File TitleConsumer – Pretest Questionnaire
AuthorAdam Rosenblatt
Last Modified ByMizrachi, Ila
File Modified2015-10-07
File Created2015-10-07

© 2024 OMB.report | Privacy Policy